Related Experiment Video
Updated: Aug 16, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
Failure of rituximab in human immunodeficiency virus-associated multicentric Castleman disease
Ségolène Neuville1, Felix Agbalika, Claire Rabian
1Department of Infectious Diseases, Saint-Louis Hospital, University of Paris, AP-HP, Paris, France.
Abstract:
Two human immunodeficiency virus-infected patients who needed etoposide therapy to control exacerbations of Castleman disease received four infusions of rituximab. Clinical and virologic relapses with increased blood human herpesvirus-8 DNA levels occurred in both patients 4 and 24 weeks later and were associated with a worsening of Kaposi sarcoma.
More Related Videos
06:08Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
Published on: February 10, 2023
09:54Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies
Published on: May 22, 2020
Related Concept Videos
Cryptococcal Meningitis
Retrovirus Life Cycles
Respiratory Syncytial Virus Disease